By Name

Alphabetical Order

By Department

In every area of practice, WilmerHale brings the insight, dedication to excellence, and commitment to client service needed for our clients to achieve their business objectives. Our five-department structure and team approach to service enable us to provide the highest level of responsiveness and access to lawyers with the most appropriate experience.

Stuart Falber represents clients in the life sciences area. For more than 20 years, Mr. Falber has served as counsel for a broad range of life sciences clients, ranging from startup private companies to mature public companies, investment banks and venture capital funds.

Mr. Falber's practice focuses on corporate and securities law, with an emphasis on private and public company counseling; representation of issuers, investment banks and investors in venture capital transactions, public offerings and other financing transactions; mergers and acquisitions, including public and private company acquisitions and dispositions, asset acquisitions and sales, and public and private company spinoffs; and corporate collaborations and licensing transactions.

Professional Activities

Mr. Falber is a member of the American Bar Association, the Massachusetts Bar Association and the Boston Bar Association, as well as the Boston Bar Association's 2017 Life Sciences Conference Advisory Committee.

Publications & News

Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, recently announced the closing of a $100 million Series B financing.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced the closing of its initial public offering.

Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a $30 million Series A financing.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a $60 million Series E preferred stock financing.

Best Lawyers in America®—the oldest and most respected peer-review publication in the legal industry—recognizes 107 WilmerHale lawyers and names nine partners as Lawyers of the Year in its 24th edition.

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

Tetraphase Pharmaceuticals, Inc. has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million.

Bar Admissions

In every area of practice, WilmerHale brings the insight, dedication to excellence, and commitment to client service needed for our clients to achieve their business objectives. Our five-department structure and team approach to service enable us to provide the highest level of responsiveness and access to lawyers with the most appropriate experience.